Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 12;11(4):901-4.
doi: 10.5114/aoms.2015.48546. Epub 2015 Aug 11.

Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland

Iwona Stelmach  1 , Paweł Majak  2 , Joanna Jerzyńska  2 , Magdalena Bojo  2 , Łukasz Cichalewski  2 , Katarzyna Smejda  2
Affiliations

Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland

Iwona Stelmach et al. Arch Med Sci. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of asthma exacerbations (A) and hospitalizations due to asthma exacerbations (B) in each participant 12 months before and 12 months after treatment with omalizumab. Relative change from baseline in FEV1 (C) and daily ICS dose (D) after 6 and 12 months in each patient; both parameters were calculated as follows: (value after – value before)/value before × 100%. Participants with add-on therapy with montelukast sodium (LTRA) and/or a long-acting-β2 agonist (LABA) before and after 12 months of omalizumab (E). In Figures A–D data are presented as the value for each participant and with median together with lower and upper quartiles. In Figure E data are presented as the percentage of observations
See this image and copyright information in PMC

References

    1. Kopp MV. Role of immunomodulators in allergen-specific immunotherapy. Allergy. 2011;66:792–7. - PubMed
    1. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005–15. - PMC - PubMed
    1. Pavord ID, Bush A. Anti-IgE for asthma in inner-city children. N Engl J Med. 2011;364:2556–7. - PubMed
    1. Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97:604–9. - PubMed
    1. Mathew J, Aronow WS, Chandy D. Therapeutic options for severe asthma. Arch Med Sci. 2012;8:589–97. - PMC - PubMed

LinkOut - more resources